Rucha Patil: Our ”Factor VIII Inhibitor Point-of-Care Diagnostic” Is Successfully Transferred at Science-Tech
Rucha Patil, Scientist at Department of Haemostasis and Thrombosis, ICMR- National Institute of Immunohaematology, reposted from ICMR-NIRBID on LinkedIn:
”Reposting with immense pride and gratitude
Truly delighted to see our ‘Factor VIII Inhibitor Point-of-Care Diagnostic’ successfully transferred at Science–Tech’ on National Technology Day 2026.
Grateful to my wonderful team – Sharda Shanbhag, Sweta Kaskar, and Moni Singh – and honoured that this milestone was achieved in the presence of Hon’ble Minister Dr Jitendra Singh .
Proud to see this innovation licensed to Meril Pvt Ltd – bringing us a step closer to accessible and affordable hemophilia diagnostics.”
Quoting ICMR-National Institute for Research on Blood and Immune Disorders, (ICMR-NIRBID)‘s post:
”ICMR–NIRBID is especially proud to highlight the successful technology transfer of its novel ‘Factor VIII Inhibitor Point-of-Care Diagnostic’, developed by Rucha Patil, Sharda Shanbhag, Sweta Kaskar, and Moni Singh, at the national programme Science–Tech’ held on the occasion of National Technology Day 2026 at BRIC–National Institute of Immunology, in the presence of Jitendra Singh, Hon’ble Minister of State (Independent Charge), Ministry of Science and Technology and Ministry of Earth Sciences; MoS, PMO; Ministry of Personnel, Public Grievances and Pensions; Department of Atomic Energy; and Department of Space, Government of India.
This innovation has been licensed to Meril Life Sciences, marking a significant advancement toward enhancing accessible and timely diagnostics for hemophilia care.
The novel FVIII inhibitor POCT is a low-cost, point-of-care lateral flow assay based on gold nanoparticle technology, enabling rapid detection of FVIII inhibitors at approximately one-twentieth the cost of the gold-standard assay, while remaining unaffected by non-factor therapies.”
Stay updated with Hemostasis Today.
-
Sep 25, 2026, 07:25Varun Capoor: How Therapeutic Apheresis and Transfusion Medicine Can Complement Clinical Management in SCD
-
Sep 25, 2026, 07:14Manshi Kesharwani: SAK-GQDs Modulate Thrombus Burden and Endothelial Function in Deep Vein Thrombosis
-
Sep 25, 2026, 06:20Farjah Hassan Algahtani: How Can We Better Identify Patients at Risk of Blood Clots after Metabolic and Bariatric Surgery?
-
Sep 25, 2026, 05:59Carla Lewis: Kids Conquering Sickle Disease Joins Nemours Children’s Hospital for 2nd Annual Awareness Event
-
Sep 25, 2026, 05:47Omid Seidizadeh: Evolutionary Constraint and Population Variation Across Coagulation Genes
-
Sep 25, 2026, 05:40Gerald Bertrand: Presenting UMi-NGS Non-Invasive Foetal HPA Genotyping at DGTI 2026
-
Sep 25, 2026, 05:33Urge Congress to support the Sickle Cell Disease Comprehensive Care Act – ASH
-
Sep 25, 2026, 05:24Isabelle Mahé: Reduced-Dose Apixaban in Extended CAT Treatment
-
Sep 25, 2026, 05:15Maria Cherska: High Cholesterol Isn’t Always Diet or Lifestyle – Sometimes It’s Genetic